Oncology top area for non-industry sponsored clinical trials
Researchers have found that oncology therapies had the most investment in non-industry sponsored clinical trials last year.
According to new research, from Globaldata, oncology was the top therapy area for non-industry sponsored clinical trials in 2019, making up 25.7 percent of all clinical trials. Therapies for the central nervous system (CNS) came in second with 23.5 percent, followed by:
- cardiovascular at 8.9 percent
- infectious disease at 8.5 percent
- metabolic disorders at 7.4 percent.
Oncology, CNS, cardiovascular and infectious disease clinical trials all showed an increase in 2019 from 2018, say the researchers.
Scotty Chung-Siu, Senior Analyst at GlobalData comments: “A small number of Phase 0, Phase I/II, Phase II/III and Phase III/IV trials were combined with Phase I, Phase II, Phase III and Phase IV trials, respectively. When looking at non-industry-sponsored clinical trials since 2017, there has been a steady increase, from 32.1 percent of all clinical trials that year to 34.5 percent in 2019.”
“When looking at non-industry-sponsored clinical trials in 2019, it can be seen that Phase II clinical trials outnumbered all other phases. Phase II clinical trials made up 49.7 percent of all clinical trials in 2019, with Phase IV following with 19.4 percent, Phase I next with 16.4 percent and Phase III with 14.5 percent,” Chung-Siu concluded.
Further research has found that oncology is set to dominate much of the clinical trial activity this year, with industry-sponsored trials to account for the majority of studies. However, other findings reveal that there are more non industry-sponsored trials with a projected completion date in 2020 than industry sponsored trials.